(NASDAQ:EVAX)  AMERICAN DEPOSITORY SHARE: up more than 40% in pr-market trading this morning on news of successful cancer trial.

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02

OMX   “GlobeNewswire – EU Press Releases”

COPENHAGEN, Denmark, May 10, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has successfully produced all batches of personalized cancer immunotherapies for all patients enrolled in the Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma.

Read entire article: https://www.globenewswire.com/news-release/2022/05/10/2439615/0/en/Evaxion-Biotech-Announces-Successful-Production-of-Personalized-Cancer-Immunotherapies-in-Phase-1-2a-Clinical-Trial-for-EVX-02.html


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist